Serum fibrosis markers could aid in the prediction of factor for successful oral antiviral treatment in hepatitis C

Background It has been demonstrated that there may be a relationship between liver fibrosis and serum biomarkers. The aim of this study was to investigate pre- and postoral antiviral therapy levels of these biomarkers and their relationship with other fibrotic parameters in hepatitis C virus (HCV) patients. Methods The study group comprised HCV patients who were treated with oral antiviral regimens. Prior to, and 8 months after the treatment, serum biomarkers, including transforming growth factor-beta (TGF-beta), chitinase-3-like protein 1 (YKL-40), collagen type IV, matrix metalloproteinases (MMPs) and hyaluronic acid levels, were examined and fibrosis-4 (Fib-4) and aspartate aminotransferase to platelet ratio index (APRI) scores were calculated at the same times. Results In total, 45 HCV patients (aged between 27 and 86 years) participated. Of these 20 (44.4%) were cirrhotic and 25 (55.6%) were noncirrhotic. The concentrations of YKL-40 (P = 0.01) and TGF-beta (P = 0.032) after treatment were significantly higher than the pretreatment values, whereas hyaluronic acid concentrations decreased after treatment (P = 0.001). Noncirrhotic patients had significantly higher (P = 0.03) YKL-40 levels prior to therapy compared to cirrhotic patients. Median MMP-2 concentrations were higher in men than in women (P = 0.001). Prior to treatment, TGF-beta, YKL-40 and collagen type IV levels were negatively correlated with Fib-4 scores, whereas only TGF-beta and YKL-40 concentrations were negatively correlated with APRI scores. Conclusion YKL-40, TGF beta and hyaluronic acid may be markers for fibrotic change during oral therapy for HCV. In particular, TGF beta concentrations correlated with fibrotic indices. However, these results should be confirmed and validated by further research. Copyright (C) 2021 Wolters Kluwer Health, Inc. All rights reserved.